<div id="readability-page-1"><div>RNS Number : 0222U J.P. Morgan SE 23 February 2026 FORM 8.5 (EPT/NON-RI)PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY ANEXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY (&#34;RI&#34;) STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)Rule 8.5 of the Takeover Code (the &#34;Code&#34;)1. KEY INFORMATION<div><table><tbody><tr><td>(a) Name of exempt principal trader:</td><td>J.P. Morgan SE</td></tr><tr><td>(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree</td><td>Spire Healthcare Group plc</td></tr><tr><td>(c) Name of the party to the offer with which exempt principal trader is connected:</td><td>Corporate Broker to Spire Healthcare Group PLC</td></tr><tr><td>(d) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure</td><td>20 February 2026</td></tr><tr><td>(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state &#34;N/A&#34;</td><td>N/A</td></tr></tbody></table></div>2. POSITIONS OF THE EXEMPT PRINCIPAL TRADERIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)<div><table><tbody><tr><td>Class of relevant security:</td><td colspan="4">1p ordinary</td></tr><tr><td rowspan="2"></td><td colspan="2">Interests</td><td colspan="2">Short positions</td></tr><tr><td>Number</td><td>%</td><td>Number</td><td>%</td></tr><tr><td>(1) Relevant securities owned and/or controlled:</td><td>0</td><td>0.00</td><td>49,858</td><td>0.01</td></tr><tr><td>(2) Cash-settled derivatives:</td><td>0</td><td>0.00</td><td>0</td><td>0.00</td></tr><tr><td>(3) Stock-settled derivatives (including options) and agreements to purchase/sell:</td><td>0</td><td>0.00</td><td>0</td><td>0.00</td></tr><tr><td> TOTAL:</td><td>0</td><td>0.00</td><td>49,858</td><td>0.01</td></tr></tbody></table></div>All interests and all short positions should be disclosed.Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).(b) Rights to subscribe for new securities (including directors' and other employee options)<ul><li>Class of relevant security in relation to which subscription right exists:</li><li>Details, including nature of the rights concerned and relevant percentages:</li></ul>3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADERWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.The currency of all prices and other monetary amounts should be stated.(a) Purchases and sales<div><table><tbody><tr><td>Class of relevant security</td><td>Purchases/ sales</td><td>Total number of securities</td><td>Highest price per unit paid/received</td><td>Lowest price per unit paid/received</td></tr><tr><td rowspan="2">1p ordinary</td><td>Purchase</td><td>18</td><td>1.9948 GBP</td><td>1.9881 GBP</td></tr><tr><td> Sale</td><td> 18</td><td> 1.9947 GBP</td><td> 1.9947 GBP</td></tr></tbody></table></div>(b) Cash-settled derivative transactions<ul><li>Class of relevant security</li><li>Product descriptione.g. CFD</li><li>Nature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short position</li><li>Number of reference securities</li><li>Price per unit</li></ul>(c) Stock-settled derivative transactions (including options)(i) Writing, selling, purchasing or varying<ul><li>Class of relevant security</li><li>Product description e.g. call option</li><li>Writing, purchasing, selling, varying etc.</li><li>Number of securities to which option relates</li><li>Exercise price per unit</li><li>Typee.g. American, European etc.</li><li>Expiry date</li><li>Option money paid/ received per unit</li></ul>(ii) Exercise<ul><li>Class of relevant security</li><li>Product descriptione.g. call option</li><li>Exercising/ exercised against</li><li>Number of securities</li><li>Exercise price per unit</li></ul>(d) Other dealings (including subscribing for new securities)<ul><li>Class of relevant security</li><li>Nature of dealinge.g. subscription, conversion</li><li>Details</li><li>Price per unit (if applicable)</li></ul>4. OTHER INFORMATION(a) Indemnity and other dealing arrangements<ul><li>Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state &#34;none&#34;</li><li>None</li></ul>(b) Agreements, arrangements or understandings relating to options or derivatives<ul><li>Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state &#34;none&#34;</li><li>None</li></ul>(c) Attachments<ul><li>Is a Supplemental Form 8 (Open Positions) attached?</li><li>NO</li></ul><div><table><tbody><tr><td>Date of disclosure:</td><td>23 February 2026</td></tr><tr><td>Contact name:</td><td>Hetvi Shah</td></tr><tr><td>Telephone number:</td><td>44 2034 936359</td></tr></tbody></table></div>Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0) 20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END FEOAKNBKKBKDFBB</div></div>

SCHE

J.P. Morgan SE disclosed its position regarding Spire Healthcare Group plc in accordance with Rule 8.5 of the Takeover Code. As of February 20, 2026, J.P. Morgan SE holds 49,858 ordinary shares of Spire Healthcare, representing 0.01% of the total. The disclosure includes details of recent transactions, including the purchase of 181 shares at prices ranging from £1.9881 to £1.9947. No other agreements or arrangements related to the securities were reported. The disclosure was made on February 23, 2026, by Hetvi Shah.

REG - J.P. Morgan SE Spire Healthcare Grp - Form 8.5 (EPT/NON-RI)-Spire Healthcare Group plc